Abstracts significantly (p = 0.0432) higher costs for cilostazol using a gamma GLM model. CONCLUSIONS: The gamma GLM technique is a powerful tool for modeling strictly positive skewed outcomes and should be more widely employed in pharmacoeconomic analyses.
PMD3 INCREMENTAL COST EFFECTIVENESS RATIOS AND CONFIDENCE INTERVALS-RELATIONSHIP OF CALCULATIONS WITH NNT VERSUS BOOTSTRAP METHODS

McGhan W
1 , Peterson A 1 , Kulkarni S 2 , Kamble S 1 , Shetty N 1 1 University of the Sciences, Philadelphia, PA, USA; 2 Fox Chase Cancer Center, Cheltenham, PA, USA The concept of incremental cost effectiveness ratios (ICERs) and confidence intervals (CIs) may seem complicated to many practitioners and decision makers. There is a growing body of literature regarding the use of NNT (number needed to treat) as a statistic that may be easier to understand in clinical practice. NNTs and ICERs are receiving increased attention in the interface of clinical and economic concepts. OBJECTIVE: To compare the ICER and CI results by using NNT-related calculations versus bootstrap analyses utilizing datasets from three published papers. METHODS: An NNT spreadsheet calculator was developed that generates NNT confidence intervals and incremental cost to treat calculations. Datasets with an aggregate total of over 2000 patients from three previously published pharmacoeconomic studies were analyzed with both the NNT and bootstrap ICER approach. The NNT calculator used a two by two contingency table with additional cells for including cost of each treatment. Confidence intervals (95%) were calculated for NNT and the upper and lower values of the incremental cost per successfully treated patient. In contrast, the bootstrap software utilizes each individual patient case in the datasets to generate ICER ratios and ICER confidence intervals. RESULTS: The NNT results for the mean cost needed to treat for one successful outcome showed good agreement with the bootstrap generated ICER slopes. For NNT versus bootstrap, the anti-platelet study mean ICERs were $43,729 vs. $43,742, the antidepressant comparative study ICERs were -$1648 vs. -$1647 and the antidepressant combination study ICERs were -$188,014 vs. -$188,012. Using 5th and 95th percentiles for cost of treatment multiplied by corresponding NNT confidence intervals did not generate very close agreement with the bootstrapped CIs. CON-CLUSIONS: NNT related calculations may be a method for initially analyzing local pilot data or explore the economic ramifications of a clinical publication when the full dataset is not available.
PMD4 ISHIKAWA CAUSE AND EFFECT DIAGRAMS: A USEFUL TOOL IN DESIGNING ECONOMIC ANALYSES
Salvador CG
Jefferson Medical College, Philadelphia, PA, USA; 2 Thomas Jefferson University, Philadelphia, PA, USA OBJECTIVES: Cause and effect diagrams (also known as Ishikawa or fishbone diagrams) graphically depict the relationships between a particular outcome and all of the identified factors contributing to that outcome. The diagram's structure includes a central "bone" with the topic of interest (the "head") attached at the right-hand end. Branching out from the central line are "sub-bones" that represent primary causal factors, and each of these in turn has sub-bones representing subsidiary contributing factors. METHODS: Ishikawa diagrams were originally developed and have typically been used as a tool for root cause analyses, but they also can benefit the planning of economic analyses for a particular disease state, medical technology, or other health care intervention. Recent projects conducted by the Department of Health Policy of Jefferson Medical College illustrate the value of Ishikawa diagrams in planning economic analyses. One project involved the development of an economic model related to the diagnosis and management of Crohn's disease. An Ishikawa diagram was used to organize the findings of an extensive literature review on this topic. The main categories, or "sub-bones" contributing to the cost of Crohn's included: diagnostic work-up, medication therapy, administration, hospitalization, surgery, and adverse reactions/complications. RESULTS: Many of these categories were further broken down into appropriate subcategories. In another project, this tool was used to organize and graphically depict cost factors for allogeneic blood transfusions. Identified factors contributing to total costs were organized around four main sub-bones: Acquisition, Administration, Preparation, and Adverse Events/Complications. CONCLUSIONS: In both of these projects, the constructed diagram facilitated the organization of large amounts of information, selection of key factors for inclusion in decision analytic economic models, and identification of unmeasured contributors to cost, which might influence the model's assumptions or findings. Outcomes researchers therefore are
